Clinical Effect Observation of Dapagliflozin on Type 2 Diabetes Patients with Acute Coronary Syndrome
Objective To evaluate effect of dapagliflozin on short-term prognosis of type 2 diabetes mellitus(T2MD)with acute coronary syndrome(ACS).Methods The paper chose T2DM patients with ACS in Nanjing Medical University Affiliated Brain Hospital and Pukou District Traditional Chinese Medicine Hospital of Nanjing from May 2021 to April 2023.Based on routine treatment,patients were divided into dapagliflozin group and non dapagliflozin group,with 30 cases in each group.Incidence of major adverse cardiovascular events(MACEs),protection of heart function,and effect on blood glucose and renal function were observed based on follow up of 3 months.Results Improved left ventricular ejection fraction(EF),left ventricular end diastolic diameter(LVEDD)in dapagliflozin group showed(P＜0.01),glomerular filtration rate(eGFR),fasting blood glucose showed(P＜0.05),postprandial 2-hour blood glucose and glycated hemoglobin showed(P＜0.01).Incidence of adverse reactions and major cardiovascular events in dapagliflozin group was lower than non dapagliflozin group(P＜0.05).Conclusion Addition of dapagliflozin can improve short-term prognosis of T2DM patients with ACS and reduce incidence of MACE events based on routine treatment.
DapagliflozinAcute coronary syndromeType 2 diabetesMajor adverse cardiovascular events(MACEs)Cardiac function
NETL
NSTL
万方数据
